Profound Medical Corp (PROF)

$5.70 +0.02 (0.35%)
Market Cap 170.70M
Revenue (ttm) 10.68M
Net Income (ttm) -27.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -260.49%
Debt to Equity Ratio 0.09
Volume 25,100
Avg Vol 45,972
Day's Range N/A - N/A
Shares Out 30.05M
Stochastic %K 28%
Beta 0.49
Analysts Strong Sell
Price Target $12.31

Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or phys...

Industry: Medical Devices
Sector: Healthcare
Phone: 647 476 1350
Fax: 647 847 3739
Address:
2400 Skymark Avenue, Unit 6, Mississauga, Canada
BioTuesdays
BioTuesdays Jul. 16 at 7:58 PM
Lake Street Capital Markets senior research analyst, Ben Haynor, issued a research note today on Profound Medical, reiterating his ‘buy’ rating and $11 target price on the company’s stock $PROF https://biotuesdays.com/2025/07/16/lake-street-sees-cmss-proposed-2026-tulsa-reimbursement-as-favorable/
0 · Reply
dndodd
dndodd Jul. 14 at 11:44 AM
$PROF as a follow up to a friend I introduced to Tulsa. He chose Tulsa over DaVinci (which was scheduled). He is very happy with end result no surgery and his prostate is shrunk or gone. The only complications was he had to have a catheter a little longer than expected as they totally did away with the prostrate. He traveled 500 miles to go the Tulsa route. We have a great medical community in Birmingham, Al but someone needs to be the first to buy a Tulsa as I am sure it would be a success.
0 · Reply
johntarlick
johntarlick Jul. 13 at 12:06 PM
$PROF a strange business. Over on glassdoor, it's being said a round of layoffs in the sales team took effect on July 1. Not sure what to make of this. By my tally, the 2020-2024 sales team had never numbered more than about 20. But, since the new CCO came on board last fall, it had been publicly stated that he'd be getting a sales team of no less than 40. That hadn't seemed realistic to me, but i did at least appreciate the intent of going all in on driving sales and building revenue. Now it seems like that's being walked back a little.
0 · Reply
johntarlick
johntarlick Jul. 4 at 2:15 AM
another Canadian medtech with some parallels to $PROF (Synaptive) has just emerged from bankruptcy, with some new investment and an unknown future. Much like $PROF, they pioneered a new surgical tool with image-guidance. Like TulsaPro, the Synaptive exoscope was technically best in class. Like $PROF, Synaptive struggled to place many systems. Like $PROF, Synaptive was small and somewhat under-funded compared to the competition. To be clear, Synaptive made a certain mistake that $PROF has not made. Perhaps two. But still, Synaptive was loaded to the gills with talent. It had seemed just a few years ago that their future was bright.
0 · Reply
johntarlick
johntarlick Jun. 25 at 11:33 AM
not super new, but i only just caught it. the original founder of $PROF recently co-founded a boutique concierge prostate clinic to offer tulsaPRO in Texas. Interestingly, that clinic also offers HIFU. If the founder of $PROF thinks HIFU is still a viable choice, it nicely informs the comparative long term prospects for these two related technologies.
2 · Reply
dndodd
dndodd Jun. 22 at 1:27 PM
$PROF this company seems to be totally flying under the radar of many investors. At some point it will be seen for the game changer it is.
0 · Reply
QES
QES Jun. 12 at 12:42 AM
$PROF How PROF compares to $PRCT PROF is the clear winner
3 · Reply
BioTuesdays
BioTuesdays Jun. 10 at 5:24 PM
First BPH patient treated using Profound’s TULSA-PRO with TULSA-AI Volume Reduction $PROF https://biotuesdays.com/2025/06/10/first-bph-patient-treated-using-profounds-tulsa-pro-with-tulsa-ai-volume-reduction/
1 · Reply
QES
QES Jun. 10 at 5:04 PM
$PROF Naveen Kella, M.D., Founder of The Urology Place "He has performed nearly all of his robotic prostatectomy cases in the same hospital with the same team. " Is he switching to TULSA Pro? https://www.youtube.com/watch?v=H0iedrP-aLI&t=118s
0 · Reply
QES
QES Jun. 10 at 2:26 PM
$PROF Profound Medical Announces First Commercial BPH Patient Treatment Using TULSA-PRO® with TULSA-AI® Volume Reduction the first commercial benign prostatic hyperplasia (“BPH”) treatment utilizing the TULSA-PRO® system’s new TULSA-AI® Volume Reduction Module was successfully conducted yesterday by Naveen Kella, M.D., Founder of The Urology Place and an Adjunct Assistant Professor for the UT Health Science Center San Antonio. The TULSA procedure, performed using the TULSA-PRO® system, has the potential to become a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and BPH; to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. https://www.globenewswire.com/news-release/2025/06/10/3096565/33471/en/Profound-Medical-Announces-First-Commercial-BPH-Patient-Treatment-Using-TULSA-PRO-with-TULSA-AI-Volume-Reduction.html
0 · Reply
Latest News on PROF
Profound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to Follow

Jul 24, 2025, 5:00 PM EDT - 4 days ago

Profound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to Follow

Profound Medical Annual General and Special Meeting of Shareholders Voting Results

May 14, 2025, 4:45 PM EDT - 2 months ago

Profound Medical Annual General and Special Meeting of Shareholders Voting Results

Profound Medical Corporation (PROF) Q1 2025 Earnings Conference Call Transcript

May 9, 2025, 7:17 AM EDT - 2 months ago

Profound Medical Corporation (PROF) Q1 2025 Earnings Conference Call Transcript

Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference

Apr 30, 2025, 4:30 PM EDT - 3 months ago

Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference

Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy

Apr 29, 2025, 7:30 AM EDT - 3 months ago

Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy

Profound Medical AUA 2025 Investor Event Agenda

Apr 15, 2025, 7:45 AM EDT - 3 months ago

Profound Medical AUA 2025 Investor Event Agenda

Profound Medical Corp. (PROF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 8, 2025, 10:00 AM EDT - 3 months ago

Profound Medical Corp. (PROF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

PROF Investors Have Opportunity to Join Profound Medical Corp. Fraud Investigation with the Schall Law Firm

Apr 8, 2025, 9:32 AM EDT - 3 months ago

PROF Investors Have Opportunity to Join Profound Medical Corp. Fraud Investigation with the Schall Law Firm

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Shareholders to Inquire about Securities Investigation

Apr 7, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Shareholders to Connect

Apr 6, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Shareholders to Reach Out

Apr 4, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Profound Medical Corp. (PROF) and Encourages Investors to Learn More About the Investigation

Apr 3, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Profound Medical Corp. (PROF) and Encourages Investors to Learn More About the Investigation

Profound Medical Corp. (PROF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Apr 2, 2025, 10:00 AM EDT - 4 months ago

Profound Medical Corp. (PROF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Investors to Connect

Apr 1, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Stockholders to Inquire about Securities Investigation

Mar 31, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Profound Medical Corp. (PROF) and Encourages Stockholders to Learn More About the Investigation

Mar 28, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Profound Medical Corp. (PROF) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Investors to Inquire about Securities Investigation

Mar 27, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Investors to Inquire about Securities Investigation

Wolf Haldenstein Adler Freeman & Herz LLP is investigating Profound Medical Corp. for potential violations of securities laws

Mar 26, 2025, 9:59 PM EDT - 4 months ago

Wolf Haldenstein Adler Freeman & Herz LLP is investigating Profound Medical Corp. for potential violations of securities laws

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Investors to Reach Out

Mar 26, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Stockholders to Reach Out

Mar 25, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Stockholders to Connect

Mar 24, 2025, 1:00 PM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Stockholders to Connect

Profound Medical Corporation (PROF) Q4 2024 Earnings Conference Call Transcript

Mar 6, 2025, 8:35 PM EST - 5 months ago

Profound Medical Corporation (PROF) Q4 2024 Earnings Conference Call Transcript

Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow

Feb 13, 2025, 5:00 PM EST - 5 months ago

Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow

Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues

Jan 8, 2025, 7:30 AM EST - 7 months ago

Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues

Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 8:15 AM EST - 7 months ago

Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares

Dec 10, 2024, 9:55 AM EST - 8 months ago

Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares

Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares

Dec 6, 2024, 9:04 AM EST - 8 months ago

Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares

Profound Medical Announces Proposed Public Offering of Common Shares

Dec 5, 2024, 4:48 PM EST - 8 months ago

Profound Medical Announces Proposed Public Offering of Common Shares

Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy

Dec 2, 2024, 7:30 AM EST - 8 months ago

Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy

Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant'

Nov 26, 2024, 7:45 AM EST - 8 months ago

Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant'

Profound Medical Corporation (PROF) Q3 2024 Earnings Call Transcript

Nov 10, 2024, 8:50 AM EST - 9 months ago

Profound Medical Corporation (PROF) Q3 2024 Earnings Call Transcript

Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025

Nov 4, 2024, 6:55 AM EST - 9 months ago

Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025

Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow

Oct 17, 2024, 4:30 PM EDT - 10 months ago

Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow

Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer

Oct 16, 2024, 4:15 PM EDT - 10 months ago

Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer

Profound Medical to Participate in Lake Street's Best Ideas Growth Conference

Sep 4, 2024, 4:30 PM EDT - 11 months ago

Profound Medical to Participate in Lake Street's Best Ideas Growth Conference

Profound Medical Corporation (PROF) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 11:11 PM EDT - 1 year ago

Profound Medical Corporation (PROF) Q2 2024 Earnings Call Transcript

Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow

Jul 18, 2024, 4:30 PM EDT - 1 year ago

Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow

Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases

Profound Medical Annual General Meeting of Shareholders Voting Results

May 15, 2024, 5:00 PM EDT - 1 year ago

Profound Medical Annual General Meeting of Shareholders Voting Results

Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant' AI Module that Enables Creation of an Automated TULSA Treatment Plan

May 14, 2024, 7:30 AM EDT - 1 year ago

Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant' AI Module that Enables Creation of an Automated TULSA Treatment Plan

Profound Medical Corp. (PROF) Q1 2024 Earnings Call Transcript

May 11, 2024, 1:47 PM EDT - 1 year ago

Profound Medical Corp. (PROF) Q1 2024 Earnings Call Transcript

Growing Body of Clinical Evidence Points to the Potential of Profound Medical's TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum

May 6, 2024, 4:15 PM EDT - 1 year ago

Growing Body of Clinical Evidence Points to the Potential of Profound Medical's TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum

Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow

Apr 22, 2024, 4:15 PM EDT - 1 year ago

Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow

Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

Apr 9, 2024, 7:45 AM EDT - 1 year ago

Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

Profound Medical Corp. (PROF) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 11:35 PM EST - 1 year ago

Profound Medical Corp. (PROF) Q4 2023 Earnings Call Transcript

Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results

Mar 7, 2024, 4:05 PM EST - 1 year ago

Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results

BioTuesdays
BioTuesdays Jul. 16 at 7:58 PM
Lake Street Capital Markets senior research analyst, Ben Haynor, issued a research note today on Profound Medical, reiterating his ‘buy’ rating and $11 target price on the company’s stock $PROF https://biotuesdays.com/2025/07/16/lake-street-sees-cmss-proposed-2026-tulsa-reimbursement-as-favorable/
0 · Reply
dndodd
dndodd Jul. 14 at 11:44 AM
$PROF as a follow up to a friend I introduced to Tulsa. He chose Tulsa over DaVinci (which was scheduled). He is very happy with end result no surgery and his prostate is shrunk or gone. The only complications was he had to have a catheter a little longer than expected as they totally did away with the prostrate. He traveled 500 miles to go the Tulsa route. We have a great medical community in Birmingham, Al but someone needs to be the first to buy a Tulsa as I am sure it would be a success.
0 · Reply
johntarlick
johntarlick Jul. 13 at 12:06 PM
$PROF a strange business. Over on glassdoor, it's being said a round of layoffs in the sales team took effect on July 1. Not sure what to make of this. By my tally, the 2020-2024 sales team had never numbered more than about 20. But, since the new CCO came on board last fall, it had been publicly stated that he'd be getting a sales team of no less than 40. That hadn't seemed realistic to me, but i did at least appreciate the intent of going all in on driving sales and building revenue. Now it seems like that's being walked back a little.
0 · Reply
johntarlick
johntarlick Jul. 4 at 2:15 AM
another Canadian medtech with some parallels to $PROF (Synaptive) has just emerged from bankruptcy, with some new investment and an unknown future. Much like $PROF, they pioneered a new surgical tool with image-guidance. Like TulsaPro, the Synaptive exoscope was technically best in class. Like $PROF, Synaptive struggled to place many systems. Like $PROF, Synaptive was small and somewhat under-funded compared to the competition. To be clear, Synaptive made a certain mistake that $PROF has not made. Perhaps two. But still, Synaptive was loaded to the gills with talent. It had seemed just a few years ago that their future was bright.
0 · Reply
johntarlick
johntarlick Jun. 25 at 11:33 AM
not super new, but i only just caught it. the original founder of $PROF recently co-founded a boutique concierge prostate clinic to offer tulsaPRO in Texas. Interestingly, that clinic also offers HIFU. If the founder of $PROF thinks HIFU is still a viable choice, it nicely informs the comparative long term prospects for these two related technologies.
2 · Reply
dndodd
dndodd Jun. 22 at 1:27 PM
$PROF this company seems to be totally flying under the radar of many investors. At some point it will be seen for the game changer it is.
0 · Reply
QES
QES Jun. 12 at 12:42 AM
$PROF How PROF compares to $PRCT PROF is the clear winner
3 · Reply
BioTuesdays
BioTuesdays Jun. 10 at 5:24 PM
First BPH patient treated using Profound’s TULSA-PRO with TULSA-AI Volume Reduction $PROF https://biotuesdays.com/2025/06/10/first-bph-patient-treated-using-profounds-tulsa-pro-with-tulsa-ai-volume-reduction/
1 · Reply
QES
QES Jun. 10 at 5:04 PM
$PROF Naveen Kella, M.D., Founder of The Urology Place "He has performed nearly all of his robotic prostatectomy cases in the same hospital with the same team. " Is he switching to TULSA Pro? https://www.youtube.com/watch?v=H0iedrP-aLI&t=118s
0 · Reply
QES
QES Jun. 10 at 2:26 PM
$PROF Profound Medical Announces First Commercial BPH Patient Treatment Using TULSA-PRO® with TULSA-AI® Volume Reduction the first commercial benign prostatic hyperplasia (“BPH”) treatment utilizing the TULSA-PRO® system’s new TULSA-AI® Volume Reduction Module was successfully conducted yesterday by Naveen Kella, M.D., Founder of The Urology Place and an Adjunct Assistant Professor for the UT Health Science Center San Antonio. The TULSA procedure, performed using the TULSA-PRO® system, has the potential to become a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and BPH; to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. https://www.globenewswire.com/news-release/2025/06/10/3096565/33471/en/Profound-Medical-Announces-First-Commercial-BPH-Patient-Treatment-Using-TULSA-PRO-with-TULSA-AI-Volume-Reduction.html
0 · Reply
johntarlick
johntarlick Jun. 8 at 12:31 PM
Interesting, according to barchart some insiders bought into that recent dip $PROF, but not the one I'm really watching for.
0 · Reply
johntarlick
johntarlick Jun. 5 at 11:32 AM
$PROF Interesting podcast with CEO posted on the State of Medtech channel, deep dive on a lot of the topics that don't get much detail in the quarterly calls or press releases. But there's also more than a few canards to be aware of. For example, I was a Cedara shareholder back in the day, and what happened there was very different.
1 · Reply
BioTuesdays
BioTuesdays Jun. 4 at 2:48 PM
Profound Medical today announced that it has entered into a consulting agreement with Leonard Wheeler—former NFL player, entrepreneur, author, corporate consultant, co-executive director of the NFL Legends Community, and national podcaster $PROF https://biotuesdays.com/2025/06/04/leonard-wheeler-former-nfl-player-named-global-ambassador-for-profounds-tulsa-pro/
0 · Reply
QES
QES Jun. 4 at 2:31 PM
$PROF Notice that the hiring of Laurie Vertuccio as the new Vice President of Global Marketing coincides with Profound's newly announced consulting agreement with Leonard Wheeler. “To that end, we are excited to partner with Leonard and look forward to working with him to soon launch an immersive TULSA-PRO® awareness campaign on multiple fronts, including digital media, social media, podcasting, and more.” IMO, the biggest issue for PROF is that essentially nobody knows about TULSA Pro. Looks like that should change rapidly.
0 · Reply
QES
QES May. 27 at 8:05 PM
$PROF @Tdenton16 https://www.youtube.com/watch?v=icJ64_IgXFs Don's story
0 · Reply
QES
QES May. 27 at 7:25 PM
$PROF Laurie Vertuccio has joined Profound Medical (NASDAQ:PROF; TSX:PRN) as Vice President of Global Marketing. https://www.linkedin.com/posts/vertuccio_newbeginnings-prostatecancerawareness-medicalinnovation-activity-7333188858211192833-EjSt
0 · Reply
BioTuesdays
BioTuesdays May. 27 at 7:17 PM
Accomplished medtech industry veteran, Laurie Vertuccio, has joined Profound Medical as Vice President of Global Marketing $PROF https://biotuesdays.com/2025/05/27/accomplished-medtech-industry-veteran-laurie-vertuccio-joins-profound-medical-as-vp-of-global-marketing/
0 · Reply
QES
QES May. 27 at 2:33 PM
$PROF @Tdenton16 https://biotuesdays.com/2024/01/12/satisfied-tulsa-prostate-cancer-procedure-patient-discloses-5-2-stake-in-profound-medical/
0 · Reply
QES
QES May. 27 at 2:31 PM
$PROF @Tdenton16 https://en.wikipedia.org/wiki/Don_Daseke
0 · Reply
QES
QES May. 22 at 6:21 PM
$PROF KIMS Hospitals 1 week ago Experience the future of prostate treatment with the TULSA-PRO System at KIMS Hospitals – the only hospital in India and first in South Asia to offer this breakthrough, incision-less solution for Prostate Cancer & BPH. ✅ No Scars or Surgical Cuts ✅ Radiation-Free ✅ Faster Recovery ✅ FDA Approved ✅ Safer for Sexual & Bladder Health 💡 A game-changer in prostate care – precision meets comfort.
1 · Reply
QES
QES May. 22 at 1:51 AM
$PROF India now has Tulsa Pro.
0 · Reply